Potential mechanisms underlying inflammation-enhanced aminoglycoside-induced cochleotoxicity

Meiyan Jiang, Farshid Taghizadeh, Peter Steyger

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Aminoglycoside antibiotics remain widely used for urgent clinical treatment of lifethreatening infections, despite the well-recognized risk of permanent hearing loss, i.e., cochleotoxicity. Recent studies show that aminoglycoside-induced cochleotoxicity is exacerbated by bacteriogenic-induced inflammation. This implies that those with severe bacterial infections (that induce systemic inflammation), and are treated with bactericidal aminoglycosides are at greater risk of drug-induced hearing loss than previously recognized. Incorporating this novel comorbid factor into cochleotoxicity risk prediction models will better predict which individuals are more predisposed to druginduced hearing loss. Here, we review the cellular and/or signaling mechanisms by which host-mediated inflammatory responses to infection could enhance the trafficking of systemically administered aminoglycosides into the cochlea to enhance the degree of cochleotoxicity over that in healthy preclinical models. Once verified, these mechanisms will be potential targets for novel pharmacotherapeutics that reduce the risk of druginduced hearing loss (and acute kidney damage) without compromising the life-saving bactericidal efficacy of aminoglycosides.

Original languageEnglish (US)
Article number362
JournalFrontiers in Cellular Neuroscience
Volume11
DOIs
StatePublished - Nov 21 2017

Fingerprint

Aminoglycosides
Hearing Loss
Inflammation
Cochlea
Infection
Bacterial Infections
Anti-Bacterial Agents
Kidney
Pharmaceutical Preparations

Keywords

  • Aminoglycosides
  • Bacteriogenic
  • Gentamicin
  • Infection
  • Inflammation
  • Ototoxicity
  • Sepsis
  • Virogenic

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Potential mechanisms underlying inflammation-enhanced aminoglycoside-induced cochleotoxicity. / Jiang, Meiyan; Taghizadeh, Farshid; Steyger, Peter.

In: Frontiers in Cellular Neuroscience, Vol. 11, 362, 21.11.2017.

Research output: Contribution to journalReview article

@article{de654e5a333344369c75aa34127ea5b7,
title = "Potential mechanisms underlying inflammation-enhanced aminoglycoside-induced cochleotoxicity",
abstract = "Aminoglycoside antibiotics remain widely used for urgent clinical treatment of lifethreatening infections, despite the well-recognized risk of permanent hearing loss, i.e., cochleotoxicity. Recent studies show that aminoglycoside-induced cochleotoxicity is exacerbated by bacteriogenic-induced inflammation. This implies that those with severe bacterial infections (that induce systemic inflammation), and are treated with bactericidal aminoglycosides are at greater risk of drug-induced hearing loss than previously recognized. Incorporating this novel comorbid factor into cochleotoxicity risk prediction models will better predict which individuals are more predisposed to druginduced hearing loss. Here, we review the cellular and/or signaling mechanisms by which host-mediated inflammatory responses to infection could enhance the trafficking of systemically administered aminoglycosides into the cochlea to enhance the degree of cochleotoxicity over that in healthy preclinical models. Once verified, these mechanisms will be potential targets for novel pharmacotherapeutics that reduce the risk of druginduced hearing loss (and acute kidney damage) without compromising the life-saving bactericidal efficacy of aminoglycosides.",
keywords = "Aminoglycosides, Bacteriogenic, Gentamicin, Infection, Inflammation, Ototoxicity, Sepsis, Virogenic",
author = "Meiyan Jiang and Farshid Taghizadeh and Peter Steyger",
year = "2017",
month = "11",
day = "21",
doi = "10.3389/fncel.2017.00362",
language = "English (US)",
volume = "11",
journal = "Frontiers in Cellular Neuroscience",
issn = "1662-5102",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Potential mechanisms underlying inflammation-enhanced aminoglycoside-induced cochleotoxicity

AU - Jiang, Meiyan

AU - Taghizadeh, Farshid

AU - Steyger, Peter

PY - 2017/11/21

Y1 - 2017/11/21

N2 - Aminoglycoside antibiotics remain widely used for urgent clinical treatment of lifethreatening infections, despite the well-recognized risk of permanent hearing loss, i.e., cochleotoxicity. Recent studies show that aminoglycoside-induced cochleotoxicity is exacerbated by bacteriogenic-induced inflammation. This implies that those with severe bacterial infections (that induce systemic inflammation), and are treated with bactericidal aminoglycosides are at greater risk of drug-induced hearing loss than previously recognized. Incorporating this novel comorbid factor into cochleotoxicity risk prediction models will better predict which individuals are more predisposed to druginduced hearing loss. Here, we review the cellular and/or signaling mechanisms by which host-mediated inflammatory responses to infection could enhance the trafficking of systemically administered aminoglycosides into the cochlea to enhance the degree of cochleotoxicity over that in healthy preclinical models. Once verified, these mechanisms will be potential targets for novel pharmacotherapeutics that reduce the risk of druginduced hearing loss (and acute kidney damage) without compromising the life-saving bactericidal efficacy of aminoglycosides.

AB - Aminoglycoside antibiotics remain widely used for urgent clinical treatment of lifethreatening infections, despite the well-recognized risk of permanent hearing loss, i.e., cochleotoxicity. Recent studies show that aminoglycoside-induced cochleotoxicity is exacerbated by bacteriogenic-induced inflammation. This implies that those with severe bacterial infections (that induce systemic inflammation), and are treated with bactericidal aminoglycosides are at greater risk of drug-induced hearing loss than previously recognized. Incorporating this novel comorbid factor into cochleotoxicity risk prediction models will better predict which individuals are more predisposed to druginduced hearing loss. Here, we review the cellular and/or signaling mechanisms by which host-mediated inflammatory responses to infection could enhance the trafficking of systemically administered aminoglycosides into the cochlea to enhance the degree of cochleotoxicity over that in healthy preclinical models. Once verified, these mechanisms will be potential targets for novel pharmacotherapeutics that reduce the risk of druginduced hearing loss (and acute kidney damage) without compromising the life-saving bactericidal efficacy of aminoglycosides.

KW - Aminoglycosides

KW - Bacteriogenic

KW - Gentamicin

KW - Infection

KW - Inflammation

KW - Ototoxicity

KW - Sepsis

KW - Virogenic

UR - http://www.scopus.com/inward/record.url?scp=85040938489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040938489&partnerID=8YFLogxK

U2 - 10.3389/fncel.2017.00362

DO - 10.3389/fncel.2017.00362

M3 - Review article

VL - 11

JO - Frontiers in Cellular Neuroscience

JF - Frontiers in Cellular Neuroscience

SN - 1662-5102

M1 - 362

ER -